All In Biotech

Drug Trial Radar · NCT07226206

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Apr 30, 2032

Study completion Apr 30, 2032

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and tolerability of SPK-8011QQ in adult males with moderately severe to severe hemophilia A.

Conditions

  • Hemophilia A

Interventions

  • SPK-8011QQDrug

    Participants will receive IV SPK-8011QQ

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of participants with adverse events (AEs)Time frame: Up to approximately 5 years
  2. Severity of AEs as determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 grading scaleTime frame: Up to approximately 5 years
  3. Incidence of adverse events of special interest (AESIs)Time frame: Up to approximately 5 years
  4. Incidence of serious adverse events (SAEs)Time frame: Up to approximately 5 years
  5. Incidence of treatment-related AEsTime frame: Up to approximately 5 years
  6. Number of participants with abnormal laboratory valuesTime frame: Up to approximately 5 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Inherited Blood Disorders

    Orange, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Kaiser Permanente

    Vallejo, California · Recruiting

  • Yale School of Medicine

    New Haven, Connecticut · Recruiting

  • Newark Beth Israel Medical Center

    Newark, New Jersey · Recruiting

  • New York Presbyterian Hospital - Weill-Cornell

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.